Drew Angerer/Getty
- Sam Altman put $180 million into Retro Biosciences, a company that aims to delay death by 10 years.
- Altman's interest in longevity research dates back at least eight years, per the MIT Technology Review.
- This was after he heard of research that rejuvenated old mice by stitching them together with young ones.
OpenAI CEO Sam Altman already gave us ChatGPT, but he also has his sights set on another goal: defying death.